Enstitü Araştırmacıları
Güncel Yayınlar
Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis
Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis
Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F
BACKGROUND:
The knowledge that persistent human papillomavirus (HPV) infection is the main cause of cervical cancer has resulted in the development of prophylactic vaccines to prevent HPV infection and HPV assays that detect nucleic acids of the virus. WHO has launched a Global Initiative to scale up preventive, screening, and treatment interventions to eliminate cervical cancer as a public health problem during the 21st century. Therefore, our study aimed to assess the existing burden of cervical cancer as a baseline from which to assess the effect of this initiative.
METHODS: For this worldwide analysis, we used data of cancer estimates from 185 countries from the Global Cancer Observatory 2018 database. We used a hierarchy of methods dependent on the availability and quality of the source information from population-based cancer registries to estimate incidence of cervical cancer. For estimation of cervical cancer mortality, we used the WHO mortality database. Countries were grouped in 21 subcontinents and were also categorised as high-resource or lower-resource countries, on the basis of their Human Development Index. We calculated the number of cervical cancer cases and deaths in a given country, directly age-standardised incidence and mortality rate of cervical cancer, indirectly standardised incidence ratio and mortality ratio, cumulative incidence and mortality rate, and average age at diagnosis.
FINDINGS:Approximately 570 000 cases of cervical cancer and 311 000 deaths from the disease occurred in 2018. Cervical cancer was the fourth most common cancer in women, ranking after breast cancer (2·1 million cases), colorectal cancer (0·8 million) and lung cancer (0·7 million). The estimated age-standardised incidence of cervical cancer was 13·1 per 100 000 women globally and varied widely among countries, with rates ranging from less than 2 to 75 per 100 000 women. Cervical cancer was the leading cause of cancer-related death in women in eastern, western, middle, and southern Africa. The highest incidence was estimated in Eswatini, with approximately 6·5% of women developing cervical cancer before age 75 years. China and India together contributed more than a third of the global cervical burden, with 106 000 cases in China and 97 000 cases in India, and 48 000 deaths in China and 60 000 deaths in India. Globally, the average age at diagnosis of cervical cancer was 53 years, ranging from 44 years (Vanuatu) to 68 years (Singapore). The global average age at death from cervical cancer was 59 years, ranging from 45 years (Vanuatu) to 76 years (Martinique). Cervical cancer ranked in the top three cancers affecting women younger than 45 years in 146 (79%) of 185 countries assessed.
INTERPRETATION:Cervical cancer continues to be a major public health problem affecting middle-aged women, particularly in less-resourced countries. The global scale-up of HPV vaccination and HPV-based screening-including self-sampling-has potential to make cervical cancer a rare disease in the decades to come. Our study could help shape and monitor the initiative to eliminate cervical cancer as a major public health problem.
The knowledge that persistent human papillomavirus (HPV) infection is the main cause of cervical cancer has resulted in the development of prophylactic vaccines to prevent HPV infection and HPV assays that detect nucleic acids of the virus. WHO has launched a Global Initiative to scale up preventive, screening, and treatment interventions to eliminate cervical cancer as a public health problem during the 21st century. Therefore, our study aimed to assess the existing burden of cervical cancer as a baseline from which to assess the effect of this initiative.
METHODS: For this worldwide analysis, we used data of cancer estimates from 185 countries from the Global Cancer Observatory 2018 database. We used a hierarchy of methods dependent on the availability and quality of the source information from population-based cancer registries to estimate incidence of cervical cancer. For estimation of cervical cancer mortality, we used the WHO mortality database. Countries were grouped in 21 subcontinents and were also categorised as high-resource or lower-resource countries, on the basis of their Human Development Index. We calculated the number of cervical cancer cases and deaths in a given country, directly age-standardised incidence and mortality rate of cervical cancer, indirectly standardised incidence ratio and mortality ratio, cumulative incidence and mortality rate, and average age at diagnosis.
FINDINGS:Approximately 570 000 cases of cervical cancer and 311 000 deaths from the disease occurred in 2018. Cervical cancer was the fourth most common cancer in women, ranking after breast cancer (2·1 million cases), colorectal cancer (0·8 million) and lung cancer (0·7 million). The estimated age-standardised incidence of cervical cancer was 13·1 per 100 000 women globally and varied widely among countries, with rates ranging from less than 2 to 75 per 100 000 women. Cervical cancer was the leading cause of cancer-related death in women in eastern, western, middle, and southern Africa. The highest incidence was estimated in Eswatini, with approximately 6·5% of women developing cervical cancer before age 75 years. China and India together contributed more than a third of the global cervical burden, with 106 000 cases in China and 97 000 cases in India, and 48 000 deaths in China and 60 000 deaths in India. Globally, the average age at diagnosis of cervical cancer was 53 years, ranging from 44 years (Vanuatu) to 68 years (Singapore). The global average age at death from cervical cancer was 59 years, ranging from 45 years (Vanuatu) to 76 years (Martinique). Cervical cancer ranked in the top three cancers affecting women younger than 45 years in 146 (79%) of 185 countries assessed.
INTERPRETATION:Cervical cancer continues to be a major public health problem affecting middle-aged women, particularly in less-resourced countries. The global scale-up of HPV vaccination and HPV-based screening-including self-sampling-has potential to make cervical cancer a rare disease in the decades to come. Our study could help shape and monitor the initiative to eliminate cervical cancer as a major public health problem.
Mezunlarımız
Aynur Ünalp
Bilim Uzmanlığı - 1993
Mutlu Hayran
Bilim Uzmanlığı - 1997
İsmail Çelik
Bilim Uzmanlığı - 1999
Meltem Şengelen
Bilim Uzmanlığı - 2002
Ahmet H. Türkdemir
Bilim Uzmanlığı - 2003
Mustafa Erman
Bilim Uzmanlığı - 2009
Saadettin Kılıçkap
Bilim Uzmanlığı - 2009
Didem Ş. Dede
Bilim Uzmanlığı - 2010
Deniz Yüce
Bilim Uzmanlığı - 2011
Ömer Dizdar
Bilim Uzmanlığı - 2017
Ece Esin
Bilim Uzmanlığı - 2017
Beril Hüseyin
Bilim Uzmanlığı - 2018
Duyurular
|
Enstitümüzce Toplumsal Katkı Sağlanan Aktiviteler
14 Şubat 2025 |
|
Enstitümüzde 2024 Yılında Hibe Alınan Projeler
14 Şubat 2025 |
|
17. Hacettepe Onkoloji Sempozyumu
18 Ekim 2024 |
|
Enstitümüzden Uluslararası Ortaklı Yayınlarımız
13 Şubat 2025 |
|
Enstitümüzden Seçilmiş Q1 2024 Yayınları
23 Temmuz 2024 |
13 Aralık 2023 |
21 Kasım 2023 |
|
18. ULUSAL KANSERLİ HASTALAR KONGRESİ Ankara Üniversitesi Tıp Fakültesi İbn-i Sina Hastanesi Hasan Ali Yücel Konferans Salonu) 03 Nisan 2023 |
15 Aralık 2022 |
|
Onkoloji Hemşireliği Sertifika Programı (7-25 Kasım 2022)
11 Kasım 2022 |
21 Ekim 2022 |
|
Mezunumuz, TEKNOFEST’te Türkiye birincisi oldu.
29 Eylül 2022 |
|
Hacettepe Üniversitesi Kanser Enstitüsü Öğretim Görevlisi Alımı Sınav Sonucu */ ?>
30.12.2021 tarihinde ilan edilen 1 Adet Kanser Enstitüsü Öğretim Görevlisi (Uygulamalı Birim) Kadrosu için, 2547 Sayılı Kanunun ilgili maddeleri ve 09.11.2018 tarih ve 30590 Sayılı Resmi Gazetede Yayımlanan "Öğretim Üyesi Dışındaki Öğretim Elemanı Kadrolarına Yapılacak Atamalarda Uygulanacak Merkezi Sınav İle Giriş Sınavlarına İlişkin Usul ve Esaslar Hakkında Yönetmelik" hükümleri uyarınca yapılan Sınav Sonucunda; Atanmaya hak kazanan aday aşağıda belirtilmiştir. 
25 Ocak 2022 |
|
14. Hacettepe Üniversitesi Kanser Enstitüsü Sempozyumu Onkoloji 2021 sunumlarına ulaşmak için tıklayınız */ ?> 08 Aralık 2021 |
|
Hacettepe Üniversitesi Onkoloji Hastanesi Hemşire Müdürlüğü tarafından Enfeksiyon Kontrol Önlemleri konusunda düzenlenecek olan eğitim toplantıları serisinin takvimi yayınlanmıştır. İlgili ilana ulaşmak için tıklayınız.
13 Şubat 2020 |
|
Uluslararası Kanser Araştırmaları Kurumu (The International Agency for Research on Cancer - IARC) tarafından 4 Şubat 2020 tarihinde Dünya Kanser Gününün 20. Yılı için yayılanan Dünya Kanser Raporu: Kanserden Korunma İçin Kanser Araştırmaları raporuna yukarıdaki "Faydalı Bağlantılar" sekmesinden ulaşabilirsiniz. 5 Şubat 2020 |
|
9 Ocak 2020 tarihinde Prof. Dr. Pınar Duygulu Şahin tarafından enstitümüzde verilen "Sağlık İçin Yapay Zeka" konulu konferans sunumu web sitemize yüklenmiştir. Sunumu görüntülemek için tıklayınız.
10 Ocak 2020 |